Gray JW - Search Results

1

Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Seviour EG, et al. Among authors: gray jw. Oncogene. 2016 Feb 11;35(6):691-701. doi: 10.1038/onc.2014.469. Epub 2015 Feb 2. Oncogene. 2016. PMID: 25639871 Free PMC article.

2

ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis.

Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, Benz CC. Chang CH, et al. Among authors: gray jw. Oncogene. 1997 Apr 3;14(13):1617-22. doi: 10.1038/sj.onc.1200978. Oncogene. 1997. PMID: 9129154

3

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr. Yu Y, et al. Among authors: gray jw. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. doi: 10.1073/pnas.96.1.214. Proc Natl Acad Sci U S A. 1999. PMID: 9874798 Free PMC article.

4

PIK3CA is implicated as an oncogene in ovarian cancer.

Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. Shayesteh L, et al. Among authors: gray jw. Nat Genet. 1999 Jan;21(1):99-102. doi: 10.1038/5042. Nat Genet. 1999. PMID: 9916799

5

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. Hu L, et al. Clin Cancer Res. 2000 Mar;6(3):880-6. Clin Cancer Res. 2000. PMID: 10741711

6

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. Mills GB, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. doi: 10.1016/s0093-7754(01)90290-8. Semin Oncol. 2001. PMID: 11706404 Review.

7

Specific keynote: molecular therapeutics in ovarian cancer.

Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.

8

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Mills GB, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. doi: 10.1053/j.seminoncol.2003.08.011. Semin Oncol. 2003. PMID: 14613030 Review.

9

The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.

Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. Cheng KW, et al. Among authors: gray jw. Nat Med. 2004 Nov;10(11):1251-6. doi: 10.1038/nm1125. Epub 2004 Oct 24. Nat Med. 2004. PMID: 15502842

10

Emerging role of RAB GTPases in cancer and human disease.

Cheng KW, Lahad JP, Gray JW, Mills GB. Cheng KW, et al. Among authors: gray jw. Cancer Res. 2005 Apr 1;65(7):2516-9. doi: 10.1158/0008-5472.CAN-05-0573. Cancer Res. 2005. PMID: 15805241 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

515 results

Search Page